Incannex Healthcare Files 8-K for Material Agreement

TL;DR

Incannex Healthcare signed a big deal on Oct 9th, filed an 8-K. Details inside.

AI Summary

Incannex Healthcare Inc. filed an 8-K on October 15, 2024, reporting a material definitive agreement entered into on October 9, 2024. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Norwest, NSW, Australia.

Why It Matters

This filing indicates a significant new agreement for Incannex Healthcare, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided text.

Key Players & Entities

• Incannex Healthcare Inc. (company) — Registrant
• October 9, 2024 (date) — Date of earliest event reported
• October 15, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IXHL The Nasdaq
• $6.9 million — 2024, Incannex received approximately A$6.9 million as the initial drawdown amount. This f
• $9,373,623 — funding for the group, as the expected A$9,373,623 in refunds from the 2023 and 2024 finan

Filing Documents

• ea0217601-8k_incannex.htm (8-K) — 29KB
• ea021760101ex10-1_incannex.htm (EX-10.1) — 595KB
• ex10-1_001.jpg (GRAPHIC) — 4KB
• ex10-1_002.jpg (GRAPHIC) — 7KB
• 0001213900-24-087764.txt ( ) — 888KB
• ixhl-20241009.xsd (EX-101.SCH) — 3KB
• ixhl-20241009_lab.xml (EX-101.LAB) — 33KB
• ixhl-20241009_pre.xml (EX-101.PRE) — 22KB
• ea0217601-8k_incannex_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 9, 2024, Incannex Healthcare Pty Ltd ("Incannex"), a wholly owned subsidiary of Incannex Helathcare Inc. entered into a Facility Agreement with FC Credit Pty Ltd, pursuant to which, on October 10, 2024, Incannex received approximately A$6.9 million as the initial drawdown amount. This facility provides Incannex with immediate access to funds based on research and development ("R&D") expenses incurred during the 2023 and 2024 financial years, aligning with the end of the Australian financial year. The Research and Development Tax Incentive ("RDTI") program is a key program under the Australian government's innovation framework, designed to encourage companies to undertake R&D activities that benefit Australia. It offers a tax rebate, currently at 48.5%, for eligible R&D expenses, allowing companies to recoup almost half of their R&D spending. The program plays a crucial role in non-dilutive funding for the group, as the expected A$9,373,623 in refunds from the 2023 and 2024 financial years will not result in the issuance of additional shares or equity dilution for existing shareholders. Thus, the RDTI is particularly valuable for maintaining shareholder value while continuing significant R&D investment. Further details of the agreement are outlined in Exhibit 10.1 filed with this Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Form of Facility Agreement between Incannex Healthcare Pty Ltd, Incannex Pty Ltd, Psychennex Pty Ltd, and FC Credit Pty Ltd, dated October 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Incannex Healthcare Inc. Date: October 15, 2024 /s/ Joel Latham Name: Joel Latham Title: Chief Executive Officer and President 2

View Full Filing

View this 8-K filing on SEC EDGAR